Novartis to acquire AveXis for $8.7bn to expand gene therapy and neuroscience portfolio

Novartis, a Swiss pharmaceutical giant, has confirmed a substantial acquisition of AveXis, a US-based gene therapy company, for a total of $8.7 billion. This strategic ... Read More